Fatores de estilo de vida (por exemplo, sobrepeso/obesidade e estresse) parecem ser os principais impulsionadores da atual epidemia de diabetes do tipo 2. Condições particulares podem aumentar o risco do diabetes do tipo 2. Estes incluem doenças cardiovasculares, hipertensão, dislipidemia, obesidade, AVC, síndrome do ovário policístico, história de diabetes gestacional e problemas de saúde mental.[27]National Institute for Health and Care Excellence. Type 2 diabetes: prevention in people at high risk. September 2017 [internet publication].
https://www.nice.org.uk/guidance/ph38
[34]American Diabetes Association. Standards of care in diabetes - 2024. Diabetes Care. 2024 Jan;47(suppl 1):S1-321.
https://diabetesjournals.org/care/issue/47/Supplement_1
O National Institute for Health and Care Excellence (NICE) do Reino Unido recomenda uma estratégia de dois estágios para identificar pessoas com alto risco de diabetes do tipo 2 (e aqueles com diabetes do tipo 2 não diagnosticado): uma avaliação de risco e, se necessário, um exame de sangue confirmatório.[27]National Institute for Health and Care Excellence. Type 2 diabetes: prevention in people at high risk. September 2017 [internet publication].
https://www.nice.org.uk/guidance/ph38
O NICE recomenda que os clínicos gerais (médicos de atenção primária) usem uma ferramenta de avaliação de risco baseada em computador validada para identificar as pessoas em seu registro de prática que podem estar em alto risco de diabetes do tipo 2.[27]National Institute for Health and Care Excellence. Type 2 diabetes: prevention in people at high risk. September 2017 [internet publication].
https://www.nice.org.uk/guidance/ph38
Além disso, recomenda que farmacêuticos, oftalmologistas, enfermeiros de saúde ocupacional e líderes comunitários ofereçam um questionário de autoavaliação validado ou ferramentas validadas baseadas na internet para:[27]National Institute for Health and Care Excellence. Type 2 diabetes: prevention in people at high risk. September 2017 [internet publication].
https://www.nice.org.uk/guidance/ph38
Todos os adultos com 40 anos ou mais (exceto gestantes)
Pessoas de 25 a 39 anos de etnia sul-asiática, chinesa, afro-caribenha e negras africanas (exceto gestantes)
Adultos com qualquer outra condição que aumente o risco de diabetes do tipo 2.
Aqueles com um escore de alto risco devem ser aconselhados a contatar seu clínico geral ou enfermeiro para um teste de glicemia de jejum ou HbA1c.[27]National Institute for Health and Care Excellence. Type 2 diabetes: prevention in people at high risk. September 2017 [internet publication].
https://www.nice.org.uk/guidance/ph38
Além disso, um exame de sangue também deve ser considerado, independentemente do escore de risco, para pessoas com 25 anos ou mais de ascendência sul-asiática ou chinesa cujo índice de massa corporal (IMC) seja superior a 23 kg/m².[27]National Institute for Health and Care Excellence. Type 2 diabetes: prevention in people at high risk. September 2017 [internet publication].
https://www.nice.org.uk/guidance/ph38
Pessoas identificadas como tendo alto risco de progressão para diabetes do tipo 2, ou seja, com hiperglicemia não diabética, HND (definida como glicemia de jejum de 5.5 a 6.9 mmol/L [99.0 a 124.2 mg/dL] ou HbA1c de 42 a 47 mmol/mol [6.0% a 6.4%]) devem ser encaminhadas para um programa intensivo de mudanças de estilo de vida baseado em evidências e com qualidade garantida.[27]National Institute for Health and Care Excellence. Type 2 diabetes: prevention in people at high risk. September 2017 [internet publication].
https://www.nice.org.uk/guidance/ph38
[44]NHS England. NHS diabetes prevention programme (NHS DPP) [internet publication].
https://www.england.nhs.uk/diabetes/diabetes-prevention
Na Inglaterra, um desses programas é o Programa de Prevenção da Diabetes do NHS (DPP), também denominado programa "Healthier You" (Você mais saudável).[44]NHS England. NHS diabetes prevention programme (NHS DPP) [internet publication].
https://www.england.nhs.uk/diabetes/diabetes-prevention
Ele identifica pessoas em risco de desenvolver diabetes do tipo 2 e as inclui em um programa de mudanças de estilo de vida baseado em evidências, com duração de 9 meses, que está disponível como um serviço em grupo presencial ou como um serviço digital.[44]NHS England. NHS diabetes prevention programme (NHS DPP) [internet publication].
https://www.england.nhs.uk/diabetes/diabetes-prevention
Os critérios de elegibilidade específicos para o programa são adultos (com idades entre 18 e 80 anos) com HND ou pessoas com história de diabetes mellitus gestacional prévia e normoglicemia (HbA1c <42 mmol/mol; glicemia de jejum <5.5 mmol/l).[44]NHS England. NHS diabetes prevention programme (NHS DPP) [internet publication].
https://www.england.nhs.uk/diabetes/diabetes-prevention
As pessoas no programa recebem suporte personalizado para controlar seu peso, comer de forma mais saudável e ser mais ativas fisicamente, com o serviço digital utilizando ferramentas como tecnologias vestíveis, aplicativos onde os usuários podem acessar treinadores de saúde, grupos de apoio de pares online e a capacidade para definir e monitorar metas eletronicamente.[44]NHS England. NHS diabetes prevention programme (NHS DPP) [internet publication].
https://www.england.nhs.uk/diabetes/diabetes-prevention
Este programa reduziu o risco de desenvolver diabetes do tipo 2 em mais de um terço para as pessoas que concluíram o programa.[44]NHS England. NHS diabetes prevention programme (NHS DPP) [internet publication].
https://www.england.nhs.uk/diabetes/diabetes-prevention
A investigação mostra que uma combinação de comportamentos de estilo de vida de baixo risco, como a manutenção de um peso corporal saudável, uma dieta saudável, exercícios regulares, abstinência ou cessação do tabagismo e consumo leve de álcool, está associada a um menor risco de incidência de diabetes do tipo 2.[45]Diabetes and Nutrition Study Group (DNSG) of the European Association for the Study of Diabetes (EASD). Evidence-based European recommendations for the dietary management of diabetes. Diabetologia. 2023 Jun;66(6):965-85.
https://link.springer.com/article/10.1007/s00125-023-05894-8
http://www.ncbi.nlm.nih.gov/pubmed/37069434?tool=bestpractice.com
[46]Khan TA, Field D, Chen V, et al. Combination of multiple low-risk lifestyle behaviors and incident type 2 diabetes: a systematic review and dose-response meta-analysis of prospective cohort studies. Diabetes Care. 2023 Mar 1;46(3):643-56.
https://diabetesjournals.org/care/article/46/3/643/148470/Combination-of-Multiple-Low-Risk-Lifestyle
http://www.ncbi.nlm.nih.gov/pubmed/36812419?tool=bestpractice.com
[47]Nabila S, Kim JE, Choi J, et al. Associations between modifiable risk factors and changes in glycemic status among individuals with prediabetes. Diabetes Care. 2023 Mar 1;46(3):535-43.
https://diabetesjournals.org/care/article-abstract/46/3/535/148255/Associations-Between-Modifiable-Risk-Factors-and?redirectedFrom=fulltext
http://www.ncbi.nlm.nih.gov/pubmed/36625739?tool=bestpractice.com
[48]Schlesinger S, Neuenschwander M, Ballon A, et al. Adherence to healthy lifestyles and incidence of diabetes and mortality among individuals with diabetes: a systematic review and meta-analysis of prospective studies. J Epidemiol Community Health. 2020 May;74(5):481-487.
http://www.ncbi.nlm.nih.gov/pubmed/32075860?tool=bestpractice.com
Além disso, com prevenção agressiva da obesidade em todas as faixas etárias, a diabetes do tipo 2 é potencialmente prevenível.[49]Evert AB, Dennison M, Gardner CD, et al. Nutrition therapy for adults with diabetes or prediabetes: a consensus report. Diabetes Care. 2019 May;42(5):731-54.
https://care.diabetesjournals.org/content/42/5/731.long
http://www.ncbi.nlm.nih.gov/pubmed/31000505?tool=bestpractice.com
[50]LeBlanc EL, Patnode CD, Webber EM, et al; Agency for Healthcare Research and Quality (US). Behavioral and pharmacotherapy weight loss interventions to prevent obesity-related morbidity and mortality in adults: an updated systematic review for the U.S. Preventive Services Task Force. September 2018 [internet publication].
https://www.ncbi.nlm.nih.gov/books/NBK532379
http://www.ncbi.nlm.nih.gov/pubmed/30354042?tool=bestpractice.com
Vários ensaios clínicos demonstraram que a perda de peso está associada ao atraso ou diminuição do aparecimento de diabetes do tipo 2 em adultos de alto risco, e a European Association for the Study of Diabetes recomenda que as pessoas com sobrepeso ou obesidade devem ter pelo menos 5% de perda de peso através da adoção de uma intervenção intensiva no estilo de vida.[31]Hemmingsen B, Gimenez-Perez G, Mauricio D, et al. Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus. Cochrane Database Syst Rev. 2017 Dec 4;(12):CD003054.
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003054.pub4/full
http://www.ncbi.nlm.nih.gov/pubmed/29205264?tool=bestpractice.com
[45]Diabetes and Nutrition Study Group (DNSG) of the European Association for the Study of Diabetes (EASD). Evidence-based European recommendations for the dietary management of diabetes. Diabetologia. 2023 Jun;66(6):965-85.
https://link.springer.com/article/10.1007/s00125-023-05894-8
http://www.ncbi.nlm.nih.gov/pubmed/37069434?tool=bestpractice.com
[51]Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7;346(6):393-403.
https://www.nejm.org/doi/10.1056/NEJMoa012512
http://www.ncbi.nlm.nih.gov/pubmed/11832527?tool=bestpractice.com
[52]Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care. 1997 Apr;20(4):537-44.
http://www.ncbi.nlm.nih.gov/pubmed/9096977?tool=bestpractice.com
[53]Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001 May 3;344(18):1343-50.
https://www.nejm.org/doi/full/10.1056/NEJM200105033441801
http://www.ncbi.nlm.nih.gov/pubmed/11333990?tool=bestpractice.com
[54]Knowler WC, Fowler SE, Hamman RF, et al; Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009 Nov 14;374(9702):1677-86.
http://www.ncbi.nlm.nih.gov/pubmed/19878986?tool=bestpractice.com
[55]Balk EM, Earley A, Raman G, et al. Combined diet and physical activity promotion programs to prevent type 2 diabetes among persons at increased risk: a systematic review for the Community Preventive Services Task Force. Ann Intern Med. 2015 Sep 15;163(6):437-51.
https://annals.org/aim/fullarticle/2395729/combined-diet-physical-activity-promotion-programs-prevent-type-2-diabetes
http://www.ncbi.nlm.nih.gov/pubmed/26167912?tool=bestpractice.com
A progressão de estados de HND para diabetes pode ser reduzida em 50% ao longo de 3 a 4 anos com uma perda de peso modesta (7% do peso corporal) usando-se dieta e atividade física regular.[51]Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7;346(6):393-403.
https://www.nejm.org/doi/10.1056/NEJMoa012512
http://www.ncbi.nlm.nih.gov/pubmed/11832527?tool=bestpractice.com
[
]
What are the effects of diet, physical activity, or both in people at increased risk of developing type 2 diabetes mellitus?/cca.html?targetUrl=https://cochranelibrary.com/cca/doi/10.1002/cca.1974/fullMostre-me a resposta Além disso, demonstrou-se que diversos agentes farmacológicos, incluindo metformina, inibidores de alfa-glicosidase, orlistate, agonistas do receptor de peptídeo semelhante ao glucagon 1 (GLP-1) e tiazolidinedionas reduzem a progressão da HND para o diabetes do tipo 2.[56]Gerstein HC, Yusuf S, Bosch J, et al; DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006 Sep 23;368(9541):1096-105.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(06)69420-8/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/16997664?tool=bestpractice.com
[57]Apolzan JW, Venditti EM, Edelstein SL, et al. Long-term weight loss with metformin or lifestyle intervention in the Diabetes Prevention Program Outcomes Study. Ann Intern Med. 2019 May 21;170(10):682-90.
http://www.ncbi.nlm.nih.gov/pubmed/31009939?tool=bestpractice.com
[58]Moelands SV, Lucassen PL, Akkermans RP, et al. Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus. Cochrane Database Syst Rev. 2018 Dec 28;(12):CD005061.
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005061.pub3/full
http://www.ncbi.nlm.nih.gov/pubmed/30592787?tool=bestpractice.com
[59]Hemmingsen B, Sonne DP, Metzendorf MI, et al. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev. 2017 May 10;5(5):CD012204.
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012204.pub2/full
http://www.ncbi.nlm.nih.gov/pubmed/28489279?tool=bestpractice.com
[60]Coleman RL, Scott CAB, Lang Z, et al. Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes. Cardiovasc Diabetol. 2019 Oct 17;18(1):135.
https://cardiab.biomedcentral.com/articles/10.1186/s12933-019-0933-y
http://www.ncbi.nlm.nih.gov/pubmed/31623625?tool=bestpractice.com
[
]
In people with increased risk of developing type 2 diabetes mellitus, what are the preventative effects of alpha‐glucosidase inhibitors compared with exercise/diet or placebo or metformin?/cca.html?targetUrl=https://www.cochranelibrary.com/cca/doi/10.1002/cca.2511/fullMostre-me a resposta
[
]
Can glucagon‐like peptide (GLP)‐1 analogs prevent or delay the development of type 2 diabetes?/cca.html?targetUrl=https://www.cochranelibrary.com/cca/doi/10.1002/cca.2574/fullMostre-me a resposta
[
]
For people at risk for developing type 2 diabetes mellitus, how does metformin compare with diet and exercise?/cca.html?targetUrl=https://www.cochranelibrary.com/cca/doi/10.1002/cca.2991/fullMostre-me a resposta Mudanças de estilo de vida e/ou metformina são a opção de primeira escolha para a maioria dos pacientes.[61]Roberts S, Barry E, Craig D, et al. Preventing type 2 diabetes: systematic review of studies of cost-effectiveness of lifestyle programmes and metformin, with and without screening, for pre-diabetes. BMJ Open. 2017 Nov 15;7(11):e017184.
https://bmjopen.bmj.com/content/7/11/e017184.long
http://www.ncbi.nlm.nih.gov/pubmed/29146638?tool=bestpractice.com
[62]Haw JS, Galaviz KI, Straus AN, et al. Long-term sustainability of diabetes prevention approaches: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2017 Dec 1;177(12):1808-17.
http://www.ncbi.nlm.nih.gov/pubmed/29114778?tool=bestpractice.com
[63]Herman WH, Pan Q, Edelstein SL, et al; Diabetes Prevention Program Research Group. Impact of lifestyle and metformin interventions on the risk of progression to diabetes and regression to normal glucose regulation in overweight or obese people with impaired glucose regulation. Diabetes Care. 2017 Dec;40(12):1668-77.
https://care.diabetesjournals.org/content/40/12/1668.long
http://www.ncbi.nlm.nih.gov/pubmed/29021207?tool=bestpractice.com
[64]Galaviz KI, Weber MB, Straus A, et al. Global diabetes prevention interventions: a systematic review and network meta-analysis of the real-world impact on incidence, weight, and glucose. Diabetes Care. 2018 Jul;41(7):1526-34.
https://care.diabetesjournals.org/content/41/7/1526.long
http://www.ncbi.nlm.nih.gov/pubmed/29934481?tool=bestpractice.com
Abordagens farmacológicas mais agressivas com vários agentes continuam controversas.[65]Armato JP, DeFronzo RA, Abdul-Ghani M, et al. Successful treatment of prediabetes in clinical practice using physiological assessment (STOP DIABETES). Lancet Diabetes Endocrinol. 2018 Oct;6(10):781-9.
http://www.ncbi.nlm.nih.gov/pubmed/30224284?tool=bestpractice.com
O rastreamento da HND e a redução do risco cardiovascular adequada às necessidades do indivíduo são muito importantes.[66]Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. Circulation. 2019 Sep 10;140(11):e596-e646.
https://www.ahajournals.org/doi/10.1161/CIR.0000000000000678
http://www.ncbi.nlm.nih.gov/pubmed/30879355?tool=bestpractice.com
[67]Rosenzweig JL, Bakris GL, Berglund LF, et al. Primary prevention of ASCVD and T2DM in patients at metabolic risk: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2019 Sep;104(9):3939-85.
https://academic.oup.com/jcem/article/104/9/3939/5540926
http://www.ncbi.nlm.nih.gov/pubmed/31365087?tool=bestpractice.com